Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|September 7, 2017

Merck KGaA Completes $788-Million Divestment of Biosimilars Business

Merck KGaA completes the divestment of its biosimilars business as part of its strategy to focus on developing a pipeline of innovator drugs.

Merck KGaA completed its previously announced divestment of its biosimilars business to Fresenius Kabi, a German specialty and generic pharmaceuticals company and a subsidiary of Fresenius SE & Co. KGaA, on Sep. 1, 2017 for the purchase price of EUR 656 million (US$788 million). The reduction in the purchase price from the previously announced EUR 670 million (US$806 million) is related to the phasing of R&D expenditures between signing and closing of the acquisition, according to Fresenius Kabi. The closing of the transaction follows the receipt of regulatory approvals.

Under the transaction, Fresenius Kabi paid Merck an upfront payment of EUR 156 million (US$187 million) upon closing and will pay up to EUR 500 million (US$601 million) in milestone payments, plus royalties on future product sales. In addition, the companies entered into supply and services agreements, which include drug development support and manufacturing services for biosimilars. The biosimilars pipeline is focused on oncology and autoimmune diseases and addresses a market with current annual branded sales of around $30 billion, according to Fresenius Kabi.

The biosimilars business was part of Merck’s healthcare businesses sector and is located in Vevey and Aubonne in Canton de Vaud, Switzerland. The biosimiliars business will continue to operate in both sites following completion of the transaction. The business is developing a biosimilars portfolio focused on oncology and inflammatory disorders. Merck’s decision to divest its biosimiliars business aligns with its strategy to focus on a pipeline of innovator drugs in oncology, immuno-oncology, and immunology.

“The transaction is part of our continued active portfolio management and marks another step in the transformation of Merck KGaA, Darmstadt, Germany, into a science and technology company”, said Stefan Oschmann, Merck KGaA’s chairman of the executive board and CEO, in a company press release.

In a related move executing its company strategy, Merck KGaA announced in September 2017 that it is also considering options for its Consumer Health business, including potentially selling it.

Source: Merck KGaA, Fresenius Kabi


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.